InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.00%
)
US TECH 100
19,496.00
(
0.45%
)
Dow Jones
38,834.86
(
0.00%
)
Brent Oil
84.76
(
0.07%
)
Bitcoin
65,976.92
(
1.55%
)
Post# of 23113
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

eye_ater

Send PM Follow Ignore
Followers 55
Posts 16131
Boards Moderated 0
Alias Born 07/27/2005

eye_ater

Re: TheInvisibleHand ™ post# 180

Thursday, 06/12/2008 12:42:05 PM

Thursday, June 12, 2008 12:42:05 PM

Post# of 23113
Brean Murray initiates CYTR with a Buy and price target of $3 given CytRx's non-existent enterprise value, investors are giving no value to its pipeline of six clinical-stage drugs and several preclinical programs. The firm says the current valuation is even lower than the value of its current net cash plus its stake in RXi. They also believe that their mere market valuation for the RXi stake is extremely conservative, considering that Sirna Therapeutics and Alnylam have clearly demonstrated large pharma's interest in therapeutic RNAi.
http://news.moneycentral.msn.com/provider/providerarticle.aspx?feed=BCOM&date=20080612&id=8767004


All statements are my opinion!!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up